Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus

Hayat, Sawsan; Uppal, Sandeep

doi:10.1007/s10165-006-0561-8

Cited by 13 publications

(6 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given the findings of elevated serum TNF‐α in active SLE and overexpression of TNF‐α in active lupus nephritis, TNF‐α antagonism still appears to be an attractive option for the treatment of active lupus disease. However, evidence for therapeutic efficacy of TNF‐α blockade in SLE is still limited . A recent study which reviewed the experience of using inflixmab in SLE patients had raised serious concern of fulminant sepsis and malignancy, and hence the decision to use anti‐TNF‐α blockade in SLE should not be taken lightly …”

Section: Tumour Necrosis Factor‐α (Tnf‐α)mentioning

confidence: 99%

“…However, evidence for therapeutic efficacy of TNF-a blockade in SLE is still limited. 130,131 A recent study which reviewed the experience of using inflixmab in SLE patients had raised serious concern of fulminant sepsis and malignancy, and hence the decision to use anti-TNF-a blockade in SLE should not be taken lightly. 132…”

Section: Clinical Applications Of Tnf-a In Slementioning

confidence: 99%

See 1 more Smart Citation

The role of cytokines in the pathogenesis of systemic lupus erythematosus – from bench to bedside

Yap

Lai

2013

Nephrology

View full text Add to dashboard Cite

ABSTRACT:The pathogenesis of systemic lupus erythematosus (SLE) entails a complex interaction between the different arms of the immune system. While autoantibodies production and immune complex deposition are cornered as hallmark features of SLE, there is growing evidence to propose the pathogenic role of cytokines in this disease. Examples of these cytokines include BLys, interleukin-6, interleukin-17, interleukin-18, type I interferons and tumour necrosis factor alpha. These cytokines all assume pivotal functions to orchestrate the differentiation, maturation and activation of various cell types, which would mediate local inflammatory process and tissue injury. The knowledge on these cytokines not only fosters our understanding of the disease, but also provides insights in devising biomarkers and targeted therapies. In this review, we focus on cytokines which have substantial pathogenic significance and also highlight the possible clinical applications of these cytokines.

show abstract

Section: Tumour Necrosis Factor‐α (Tnf‐α)mentioning

confidence: 99%

Section: Clinical Applications Of Tnf-a In Slementioning

confidence: 99%

The role of cytokines in the pathogenesis of systemic lupus erythematosus – from bench to bedside

Yap

Lai

2013

Nephrology

View full text Add to dashboard Cite

show abstract

“…[35] The short term use of TNF blockade might be safe and effective in some SLE patients, especially those with lupus nephritis. [36, 37]…”

Section: Anti-cytokine Therapymentioning

confidence: 99%

Current and novel therapeutics in the treatment of systemic lupus erythematosus

Yildirim‐Toruner

Diamond

2011

Journal of Allergy and Clinical Immunology

142

111

View full text Add to dashboard Cite

Systemic lupus erythematosus (SLE) is a complex autoimmune disease with significant clinical heterogeneity. Recent advances in our understanding of the genetic, molecular and cellular basis of autoimmune diseases and especially SLE have led to the application of novel and targeted treatments. While many treatment modalities are effective in lupus-prone mice, the situation is more complex in humans. This article reviews the general approach to the therapy of SLE, focusing on current approved therapies and novel approaches that might be used in the future.

show abstract

“…Thus, their use in SLE is controversial [122, 124–126]. In SLE, the use of anti-TNF blockers has been associated with polyarthritis, cutaneous manifestations, disease activity, proteinuria, and nephritis but also severe infusion reactions [127, 128]. In SjS, anti-TNF blockers have not shown any clinical efficacy [129].…”

Section: Potential Treatment Options Based On the Modulation Of Immentioning

confidence: 99%

Immune-Regulatory Mechanisms in Systemic Autoimmune and Rheumatic Diseases

Takakubo

Konttinen

2012

Clinical and Developmental Immunology

View full text Add to dashboard Cite

Systemic autoimmune and rheumatic diseases (SAIRDs) are thought to develop due to the failure of autoimmune regulation and tolerance. Current therapies, such as biologics, have improved the clinical results of SAIRDs; however, they are not curative treatments. Recently, new discoveries have been made in immune tolerance and inflammation, such as tolerogenic dendritic cells, regulatory T and B cells, Th 17 cells, inflammatory and tolerogenic cytokines, and intracellular signaling pathways. They lay the foundation for the next generation of the therapies beyond the currently used biologic therapies. New drugs should target the core processes involved in disease mechanisms with the aim to attain complete cure combined with safety and low costs compared to the biologic agents. Re-establishment of autoimmune regulation and tolerance in SAIRDs by the end of the current decade should be the final and realistic target.

show abstract

Therapeutic efficacy and safety profile of infliximab in active systemic lupus erythematosus

Cited by 13 publications

References 11 publications

The role of cytokines in the pathogenesis of systemic lupus erythematosus – from bench to bedside

The role of cytokines in the pathogenesis of systemic lupus erythematosus – from bench to bedside

Current and novel therapeutics in the treatment of systemic lupus erythematosus

Immune-Regulatory Mechanisms in Systemic Autoimmune and Rheumatic Diseases

Contact Info

Product

Resources

About